Table 1.
Newly diagnosed FL patients with known absolute natural killer cell count (ANKC) by ANKC <150/μl vs ≥150/μl. Clinical parameters are similar in both cohorts; p value > 0.05 for all variables.
| VARIABLE | ANKC < 150/μl (n=33) | ANKC ≥ 150/μl (n=42) |
|---|---|---|
|
| ||
| Median Age (range) years | 57 (35–79) | 58 (31–88) |
|
| ||
| Stage | ||
| I | 8 (24%) | 12(29%) |
| II | 6 (18%) | 7 (17%) |
| III | 8 (24%) | 11 (26%) |
| IV | 11(33%) | 12(29%) |
|
| ||
| Gender | ||
| M | 15 (45%) | 23 (55%) |
| F | 18 (55%) | 19 (45%) |
|
| ||
| FLIPI* | ||
| 1 | 17 (51%) | 25 (60%) |
| 2 | 12 (36%) | 12 (29%) |
| 3 | 3 (9%) | 4 (10%) |
|
| ||
| Number of Extranodal Sites* | ||
| 0 | 19 (58%) | 27 (66%) |
| 1 | 11 (33%) | 12 (29%) |
| 2 | 2 (6%) | 2 (5%) |
|
| ||
| Number of Nodal Sites | ||
| Median (range) | 2 (0–6) | 2 (0–6) |
|
| ||
| Performance Status | ||
| 0 | 22 (67%) | 24 (57%) |
| 1 | 11 (33%) | 17 (40%) |
| 2 | 1 (3%) | 1 (2%) |
|
| ||
| LDH | ||
| Increased | 3 (9%) | 3 (7%) |
| Normal | 29 (88%) | 38 (90%) |
| Unknown | 1 (3%) | 1 (2%) |
|
| ||
| Hemoglobin | ||
| Decreased | 2 (6%) | 3 (7%) |
| Normal | 30 (91%) | 37 (88%) |
| Unknown | 1 (3%) | 2 (5%) |
*
Two patients did not have complete data.